Frequency of mutated allele CYP2D6*4 in the Turkish population

Pharmacology

Volumn 79, Issue 4, 2007, Pages 203-206

  Koseler, Aylin ^a,b   Ilcol, Yesim Ozarda ^a   Ulus, Ismail H ^a  

^a ULUDAG UNIVERSITY   (Turkey)

^b PAMUKKALE UNIVERSITY   (Turkey)

Author keywords

CYP2D6; Polymorphism; Real time PCR

Indexed keywords

CYTOCHROME P450 2D6; FLUORESCENT DYE;

ALLELE; ARTICLE; CONTROLLED STUDY; FLUORESCENCE; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TURKEY (REPUBLIC);

CYTOCHROME P-450 CYP2D6; GENE FREQUENCY; GENETICS, POPULATION; HUMANS; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TURKEY;

EID: 34249820794     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100959     Document Type: Article

References (27)

1. 450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20: 342-349.
2. Ingelman-Sundberg M: Pharmacogenetics of cytochrome P 450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004; 25: 193-200.
3. 450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 23-37.
4. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez F: The human debrisoquine 4-hydroxylase (CYP2D6) locus: sequence and identification of polymorphic CYP2D6 gene, related gene and pseudogene. Am J Hum Genet 1989; 45: 889-904.
5. 450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284-285.
6. Bernard S, Neville KA, Nguyen AT, Lockhart DA: Interethnic differences in genetic polymorphisms of CYP2D6 in the US population: clinical implications. Oncologist 2006; 11: 126-135.
7. Bathum L, Johanson I, Ingelman-Sundberg M, Horder M, Brosen K: Ultrarapid metabolism of spartein: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction. Pharmacogenetics 1998; 8: 119-123.
8. Alvan G, Bechtel P, Iselius L, Gundert-Remy U: Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39: 533-537.
9. 450 2D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994; 46: 452-459.
10. Lee EJ, Nam YP, Hee GN: Oxidation phenotyping in Chinese and Malay populations. Clin Exp Pharmacol Physiol 1988; 15: 889-891.
11. Wang SL, Huang JD, Lai MD, Lui BH, Lai ML: Molecular basis of genetic variation in debrisoquine hyroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993; 53: 410-418.
12. 450 enzymes 2C19 and 2D6 in the Turkish population: Clin Pharmacol Ther 1999; 66: 185-192.
13. Aydin M, Hatirnaz O, Erensoy N, Ozbek U: CYP2D6 and CYP1A1 mutations in the Turkish population. Cell Biochem Funct 2005; 23: 133-135.
14. Bozkurt A, Basci NE, Isimer A, Sayal A, Kayaalp SO: Polymorphic debrisoquin metabolism in a Turkish population. Clin Pharmacol Ther 1994; 55: 399-401.
15. 450 2D6 genotyping. Clin Chem 2002; 48: 1412-1417.
16. Scordo MG, Caputi AP, D'Arrigo C, Fava G, Spina E: Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004; 50: 195-200.
17. Agundez JA, Ledesma MC, Ladero JM, Benitez J: Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995; 57: 265-269.
18. Bernal ML, Sinues B, Johansson I, McLellan R, Dahl ML, Ingelman-Sundberg M: High frequency of subjects with multiple CYP2D6 genes in a North Spanish population. Eur J Clin Pharmacol 1997: 52:A70.
19. 450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croat Med J 2003; 44: 425-428.
20. Niewinsky P, Orzechowska-Juzwenko K, Hurkacz M, Rzemislawska Z, Jazwinska-Tarnawska E, Milejski P, Forkasiewicz Z: CYP2D6 extensive, intermediate, and poor phenotypes and genotypes in a Polish population. 2002; 58: 533-535.
21. Tamminga WJ, Wemer J, Oosterhuis B, Wieling J, Wilffert B, de Leij LFMH, de Zeeuw RA, Jonkman JHG: CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol 1999; 55: 177-184.
22. Tamminga WJ, Wemder J, Oosterheuis B, de Zeeuw RA, de Leij LFMH, Jonkman JHG: The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. Eur J Clin Pharmacol 2001; 57: 717-722.
23. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F: Ultrarapid hydroxylation of debrisoquine in a Swedish population: analysis of molecular genetics basis. J Pharmacol Exp Ther 1995; 274: 516-520.
24. Yamada H, Dahl ML, Lannfelt L, Viitanen M, Windblad B, Sjöqvist F: CYP2D6 and CYP2C19 genotypes in an elderly Swedish population. 1998; 54: 479-481.
25. Griese EU, Zanger UM, Brudermanns U, Aedigk A, Mikus G, Morike K, Stuven T, Eichelbaum M: Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998; 8: 15-26.
26. Marandi T, Dahl ML, Rago L, Kiivet R, Sjoqvist F: Debrisoquin and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia. Eur J Clin Pharmacol 1997; 53: 257-260.
27. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brocmoller J, Frotschl R, Kopke K, Gerloff T, Chernov JN, Roots I: Polymorphisims of drug-metabolizng enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 2003; 59: 303-312.